CD11c
Dendritic cell
immune cell
immunophenotype
neoadjuvant chemoradiotherapy
rectal cancer
Journal
Oncoimmunology
ISSN: 2162-402X
Titre abrégé: Oncoimmunology
Pays: United States
ID NLM: 101570526
Informations de publication
Date de publication:
2023
2023
Historique:
medline:
25
7
2023
pubmed:
24
7
2023
entrez:
24
7
2023
Statut:
epublish
Résumé
Approximately 20% of locally advanced rectal cancer (LARC) patients treated preoperatively with chemoradiotherapy (CRT) achieve pathologically confirmed complete regression. However, there are no clinically implemented biomarkers measurable in biopsies that are predictive of tumor regression. Here, we conducted multiplexed immunophenotyping of rectal cancer diagnostic biopsies from 16 LARC patients treated preoperatively with CRT. We identified that patients with greater tumor regression had higher tumor infiltration of pan-T cells and IRF8
Identifiants
pubmed: 37485033
doi: 10.1080/2162402X.2023.2238506
pii: 2238506
pmc: PMC10361136
doi:
Substances chimiques
Biomarkers
0
Interferon Regulatory Factors
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2238506Informations de copyright
© 2023 The Author(s). Published with license by Taylor & Francis Group, LLC.
Déclaration de conflit d'intérêts
No potential conflict of interest was reported by the author(s).
Références
Nat Rev Immunol. 2020 Jan;20(1):7-24
pubmed: 31467405
Oncotarget. 2017 Jul 25;8(45):79793-79802
pubmed: 29108360
Nature. 2012 Feb 08;482(7385):400-4
pubmed: 22318521
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Ann Surg Oncol. 2019 May;26(5):1412-1420
pubmed: 30805807
Cancer Immunol Immunother. 2003 Jul;52(7):423-8
pubmed: 12695859
Breast Cancer Res. 2021 Mar 25;23(1):40
pubmed: 33766090
Clin Cancer Res. 2020 Oct 1;26(19):5198-5207
pubmed: 32669377
Cancers (Basel). 2020 Aug 10;12(8):
pubmed: 32784964
Gut. 2019 Oct;68(10):1820-1826
pubmed: 31097539
Radiat Oncol. 2011 May 16;6:49
pubmed: 21575175
Eur J Immunol. 2022 Nov;52(11):1750-1758
pubmed: 35106759
Ann Surg. 2021 Dec 1;274(6):e1056-e1062
pubmed: 32039985
Ann Surg Oncol. 2014 Jun;21 Suppl 3:S414-21
pubmed: 24566864
Cytometry A. 2021 Mar;99(3):231-242
pubmed: 33200508
Cytometry A. 2022 Mar;101(3):237-253
pubmed: 33840138
Front Oncol. 2021 Oct 18;11:743540
pubmed: 34733785
Br J Cancer. 2015 Dec 22;113(12):1677-86
pubmed: 26645238
Oncotarget. 2017 Mar 21;8(12):19803-19813
pubmed: 28177891
Cancers (Basel). 2021 Feb 02;13(3):
pubmed: 33540635
J Gastrointest Oncol. 2016 Aug;7(4):603-8
pubmed: 27563451
Front Immunol. 2019 Mar 29;10:602
pubmed: 30984181
Oncology. 2020;98(12):869-875
pubmed: 32799200
J Transl Med. 2007 Nov 29;5:62
pubmed: 18047662
J Immunother Cancer. 2019 Jun 20;7(1):155
pubmed: 31221219
Clin Colorectal Cancer. 2022 Mar;21(1):e1-e11
pubmed: 35123891
Lancet Gastroenterol Hepatol. 2017 Jul;2(7):501-513
pubmed: 28479372
Immunity. 2013 Oct 17;39(4):782-95
pubmed: 24138885
Nat Med. 2022 Aug;28(8):1646-1655
pubmed: 35970919
Carcinogenesis. 2011 Nov;32(11):1660-7
pubmed: 21859832